Hippocampal Atrophy
Hippocampal Atrophy - Related Videos
01:21
Detection of Brain Atrophy by Hematoxylin and Eosin Staining
0 Views •
2025
To detect brain atrophy, begin with slides carrying the deparaffinized brain sections from neurodegenerative mouse models at various ages.
10:50
Tibial Nerve Transection - A Standardized Model for Denervation-induced Skeletal Muscle Atrophy in Mice
0 Views •
Cited by 38 •
2013
The tibial nerve transection model is a well-tolerated, validated, and reproducible model of skeletal muscle atrophy. The model surgical protocol is described and demonstrated in C57Black6 mice.
08:20
Organotypic Hippocampal Slice Cultures
0 Views •
Cited by 52 •
2011
We describe a method to prepare organotypic hippocampal slices that can be easily adapted to other brain regions. Brain slices are laid on porous membranes and culture media is allowed to form an interface. This method preserves the gross architecture of the hippocampus for up to 2 weeks in culture.
01:23
Cellular Adaptation I: Introduction and Atrophy
0 Views •
2026
Cells can adapt to environmental changes to maintain function and avoid injury, a process called cellular adaptation. Adapted cells exist in a reversible intermediate state with changes in size, number, phenotype, metabolism, or function. These responses help cells meet altered physiological or pathological demands; for example, enlargement of breast and uterine tissues during pregnancy. Early adaptations may enhance function, but persistent stress eventually causes tissue damage.Types of...
02:44
Injecting Recombinant Adeno-Associated Vectors in a Spinal and Bulbar Muscular Atrophy Mouse Model
0 Views •
2025
Source:Pourshafie, N., et al. Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents. J. Vis. Exp. (2018).In this video, a spinal and bulbar muscular atrophy or SBMA-affected mouse undergoes tail vein injection of recombinant AAV (Adeno-associated vectors) vectors carrying a plasmid encoding therapeutic microRNA. The vector produces microRNA that binds to mutant AR (Androgen receptor)-mRNA (messenger ribonucleic acid),...
FAQs
Persistently elevated glucocorticoid exposure is one of the processes linked to hippocampal atrophy. Its importance in pharmacology lies in connecting a prolonged stress-related hormonal influence with structural change in a brain region required for learning and memory. Studying this relationship helps researchers examine whether candidate treatments can limit cellular damage or preserve hippocampal structure.
Neuroinflammation and excitotoxicity represent distinct but potentially interacting routes to hippocampal injury. Neuroinflammation reflects damaging inflammatory activity, whereas excitotoxicity refers to injury associated with excessive excitatory signaling. Considering both mechanisms broadens pharmacological investigation beyond volume loss alone and supports evaluation of treatments aimed at limiting the underlying cellular damage.
Reduced adult neurogenesis is one cellular process associated with hippocampal atrophy and may help explain why structural change is relevant to learning and memory. In pharmacology, it provides a mechanism for investigating how disease-related processes affect hippocampal maintenance. Candidate treatments can therefore be evaluated for their ability to preserve structure while limiting damage linked to impaired neurogenesis.
Hippocampal atrophy can reflect the combined influence of chronic glucocorticoid exposure, neuroinflammation, excitotoxicity, vascular injury, and reduced adult neurogenesis. These mechanisms need not be treated as mutually exclusive explanations. Their interaction provides a broader framework for interpreting structural change and for studying whether a pharmacological intervention affects one damaging pathway or several processes at once.
Researchers study hippocampal atrophy as a structural biomarker by relating changes in hippocampal structure to disease progression and cognitive outcomes. This approach allows pharmacology studies to examine more than symptomatic effects: they can also ask whether a candidate treatment preserves hippocampal structure or limits the cellular damage associated with disease-related decline.
The pharmacological study of hippocampal atrophy is relevant to Alzheimer’s disease, depression, and epilepsy. These disorders provide contexts for examining how structural hippocampal changes relate to cognitive outcomes and disease progression. Comparing them helps researchers assess whether preserving hippocampal structure is a broadly useful treatment objective or a disorder-specific indicator.
Treatment evaluation should relate hippocampal structure to cognitive outcomes rather than considering either measure in isolation. A candidate therapy may be examined for evidence that it preserves hippocampal structure or limits underlying cellular damage, while researchers also assess relevance to memory and learning. Together, these outcomes connect pharmacological action with potential functional benefit.
Because the hippocampus supports memory and learning, its structural changes offer a way to connect biological injury with cognitive consequences. In pharmacology, this connection helps researchers interpret whether disease progression is accompanied by impaired memory formation or retrieval and whether treatment-related preservation of hippocampal structure corresponds to better cognitive outcomes.